Train your school staff. Download or order the Anaphylaxis: Know It. See It. Treat It. Training Video.


BioRidge Pharma facilitates the certification and fulfillment
of the EpiPen4Schools® orders.
The EpiPen4Schools® program helps improve access to epinephrine in the event a person experiences a life-threatening allergic reaction (anaphylaxis) in the school setting.
The program offers:
  • Four free EpiPen® (epinephrine injection, USP) or EpiPen Jr® (epinephrine injection, USP) Auto-Injectors in the form of two EpiPen 2-Pak® cartons, two EpiPen Jr 2-Pak® cartons or one 2-Pak of each kind.
  • Free replenishment product in the event that the free supply is used to respond to a life-threatening allergic reaction.
  • A convenient storage unit, the EpiLocker, to store EpiPen 2-Pak® and EpiPen Jr 2-Pak® cartons received through the program.
  • Anaphylaxis: Know It. See It. Treat It. Training Video, featuring an anaphylaxis overview and a step-by-step demonstration of how to administer EpiPen® Auto-Injector.
  • EpiPen® Trainers, which contains no drug product or needle, to practice administering EpiPen® Auto-Injector.
  • Signs and Symptoms of Anaphylaxis Poster, to educate about the most common indicators of anaphylaxis and support recognition of these symptoms in the event of an emergency.
CLICK HERE to start your order.
An estimated one in 13 children in the U.S. lives with a food allergy that puts them at risk for anaphylaxis— a considerable increase from previous years. Though avoidance of allergic triggers is the only way to prevent anaphylaxis, the fact is that life happens and it’s possible for someone to experience an accidental exposure or first-time reaction.
Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical care. Carrying an epinephrine auto-injector does not prevent patients from having an anaphylactic reaction; hence, patients must avoid their triggers at all times.
For more information on anaphylaxis or EpiPen® Auto-Injectors, visit

Did you know?

Anaphylaxis can develop and progress quickly, and children and adolescents are among the most at risk.

A survey of more than 6,000 schools participating in EpiPen4Schools® revealed a total of 919 anaphylatic events among students and staff during the 2013-2014 school year. Also, the survey found:

  • More than one in five anaphylactic events occurred in the absence of an established or known allergic trigger
  • In 25% of reported anaphylaxis cases, the individual was not treated with epinephrine, the only first-line treatment for anaphylaxis
  • In those events where epinephrine auto-injector was used, nearly half (48.7%) were treated with an EpiPen® Auto-Injector provided by the EpiPen4Schools® program